ICON Public Limited (NASDAQ:ICLR - Get Free Report)'s share price hit a new 52-week low on Tuesday . The stock traded as low as $125.10 and last traded at $131.08, with a volume of 883276 shares trading hands. The stock had previously closed at $126.99.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the stock. Robert W. Baird cut their price target on shares of ICON Public from $192.00 to $160.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. The Goldman Sachs Group cut their target price on ICON Public from $180.00 to $160.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. JPMorgan Chase & Co. cut ICON Public from an "overweight" rating to a "neutral" rating and lowered their price target for the company from $265.00 to $150.00 in a research report on Tuesday, April 29th. TD Cowen cut ICON Public from a "buy" rating to a "hold" rating and cut their price objective for the company from $254.00 to $157.00 in a report on Monday, April 14th. Finally, Mizuho lowered their target price on shares of ICON Public from $200.00 to $173.00 and set an "outperform" rating on the stock in a report on Thursday, May 15th. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $213.08.
Check Out Our Latest Analysis on ICLR
ICON Public Price Performance
The company has a quick ratio of 1.34, a current ratio of 1.26 and a debt-to-equity ratio of 0.36. The stock's 50-day moving average price is $144.30 and its 200-day moving average price is $181.10. The company has a market capitalization of $10.49 billion, a price-to-earnings ratio of 13.63, a price-to-earnings-growth ratio of 1.86 and a beta of 1.23.
ICON Public (NASDAQ:ICLR - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The medical research company reported $3.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.17 by $0.02. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The firm had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.03 billion. During the same quarter in the prior year, the business earned $3.47 EPS. The business's revenue for the quarter was down 4.3% compared to the same quarter last year. Equities research analysts anticipate that ICON Public Limited will post 13.38 earnings per share for the current year.
Institutional Trading of ICON Public
Hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its holdings in shares of ICON Public by 15,701.6% in the 1st quarter. GAMMA Investing LLC now owns 68,421 shares of the medical research company's stock valued at $119,730,000 after buying an additional 67,988 shares during the last quarter. Kornitzer Capital Management Inc. KS lifted its stake in ICON Public by 40.6% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company's stock valued at $20,363,000 after acquiring an additional 28,050 shares during the last quarter. Natixis Advisors LLC grew its position in shares of ICON Public by 6.7% in the 4th quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company's stock valued at $37,279,000 after acquiring an additional 11,177 shares during the period. Foyston Gordon & Payne Inc grew its position in shares of ICON Public by 27.3% in the 4th quarter. Foyston Gordon & Payne Inc now owns 51,713 shares of the medical research company's stock valued at $10,845,000 after acquiring an additional 11,089 shares during the period. Finally, Arkadios Wealth Advisors increased its stake in shares of ICON Public by 573.7% during the 1st quarter. Arkadios Wealth Advisors now owns 7,828 shares of the medical research company's stock worth $1,370,000 after purchasing an additional 6,666 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.
ICON Public Company Profile
(
Get Free Report)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Articles
Before you consider ICON Public, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICON Public wasn't on the list.
While ICON Public currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
